著者
小山 哲史 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧
藤原 和典 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
Fujii, Taihei Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine / Center for Head and Neck Surgery, Kusatsu General Hospital
中村 陽祐 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
福原 隆宏 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
竹内 裕美 Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine 研究者総覧 KAKEN
キーワード
Basaloid squamous cell carcinoma
Cetuximab
Head and neck
Metastasis
Chemotherapy
抄録
Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and distant metastases. To date few articles regarding chemotherapy for metastatic disease have been reported, thus feasible chemotherapy is not well established. Cetuximab is a monoclonal antibody for epithelial growth factor receptor (EGFR), which has great efficacy for head and neck squamous cell carcinoma due to EGFR signaling pathway blockage. Because BSCC also highly expresses EGFR, cetuximab may be effective for BSCC. We report here a first case of recurrent BSCC in the ethmoid sinus with intracranial extension treated with cetuximab-based chemotherapy, which revealed great response in a 40-year-old man. Positron emission tomography (PET) revealed no lymph node or distant metastasis. The patient underwent chemoradiotherapy 66 Gy in 33 fractions with triweekly 100 mg/m2 cisplatin. However, 12 weeks after treatment completion PET revealed a residual tumor at the primary cancer site. Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed.
出版者
Elsevier B.V.
資料タイプ
学術雑誌論文
外部リンク
ISSN
03858146
掲載誌名
Auris Nasus Larynx
最新掲載誌名
Auris Nasus Larynx
48
6
開始ページ
1189
終了ページ
1192
発行日
2021-12
出版者DOI
著者版フラグ
著者版
著作権表記
© 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
掲載情報
Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx. 48(6), 1189-1192. 2020-07-16.
部局名
医学部・医学系研究科・医学部附属病院
言語
英語
pii
S0385-8146(20)30159-0